Factor XIII Deficiency Treatment Market is Projected to Reach US$ 400.7 Million by 2034| Fact.MR Report

The Global Factor XIII Deficiency Treatment Market will be worth US$ 210.3 million in 2023 and has been estimated to grow at a significant CAGR of 5.8% to reach US$ 400.7 Million by 2034.

The patients of deficiency of factor XIII can make blood clots but such clots are easily dissolvable, unstable and can break easily which can lead to uncontrolled bleeding for a long period of time. The severity and manifestation of deficiency differ from individual to individual which eventually differentiates the treatment based on severity.

In the majority of patients with factor XIII deficiency (80%), postnatal bleeding manifestations occur, which also involve bleeding from the umbilical stump. Other patients can have only a mild presentation of its deficiency which can be seen in later years in the life if patient experiences any traumatic injury or surgery.

Factor XIII deficiency is a genetic illness. During every pregnancy, there are approximately 25% chances that two carrier parents will pass on both the abnormal genes on to their offspring. If the parents are near relatives of one another, then the risk is far greater. Therefore, in populations where consanguineous marriages are more frequent, the risk of factor XIII deficiency is increased in the children, and hence, it is very common in such populations.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=1348

Key Takeaway from Market Study

Factor XIII Deficiency Treatment Market was valued at US$ 210.3 million in 2023.
Estimated market size for 2024 is US$ 228.0 million.
Projected to reach US$ 400.7 million by 2034.
Expected CAGR of 5.8% from 2024 to 2034.
North America holds a 35.7% market share in 2024.
United States market to grow at a CAGR of 5.9% from 2024 to 2034.

Leading Players Driving Innovation in the Factor XIII Deficiency Treatment Market:

Grifols; CSL Behring; Octapharma; LFB Group; Novo Nordisk; Other Market Players.

Factor XIII Deficiency Treatment Market: Regional Outlook:

According to epidemiology, factor XIII deficiency is more prevalent in those areas where consanguineous marriages are frequent. Therefore, the prevalence of the disorder is most common in the Middle East and Africa region. But in these regions, a majority of cases remain undiagnosed.

The market for factor XIII deficiency treatment is most potent in the MEA. Other such regions include Canada, Brazil, Mexico, and China, which are some of the most profitable regions for the factor XIII deficiency treatment. The lowest epidemiology is seen in Europe and Australia, due to which the treatment rate for the factor XIII deficiency treatment is low.

Browse Full Report: https://www.factmr.com/report/1348/factor-xiii-deficiency-treatment-market

Category-wise Insights:

Demand for replacement therapy is anticipated to account for US$ 294.9 Mn by 2034 at a growth rate of 5.9% from 2024 to 2034.

The factor XIII deficiency market is expected to assume a new shape with the rise in the application of replacement therapy. With more and more cases being detected with the condition, it has become increasingly clear to healthcare providers that early intervention of the condition is of the highest priority.

Replacement therapy, particularly with recombinant Factor XIII products, addresses the issue of deficiency, thereby virtually eradicating the risk of bleeding-related complications. The expanding pipeline is increasing the scope of the market.

The recombinant products are newer and more efficient than conventional plasma derived products. They have better safety profile too. Due to these developments, the risk associated with transmission of infectious disease has decreased which ultimately decreases transfusion-associated complications.

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the factor XIII deficiency treatment market, presenting historical demand data (2018 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights into the market based on treatment type, patient type, distribution channel, and region. By treatment type, the market includes Replacement Therapy, Fresh Frozen Plasma Treatment, Factor XIII Concentrate, Supportive Treatment, Blood Transfusion, and Pain Management. Based on patient type, it is divided into Congenital Factor XIII Deficiency and Acquired Factor XIII Deficiency. The distribution channels for these treatments comprise Hospital Pharmacies, Retail Pharmacies, and Blood Banks. Geographically, the market is categorized into North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and the Middle East & Africa.

Explore More Related Studies Published by Fact.MR Research:

Optical Microscopes Market: https://www.factmr.com/report/optical-microscopes-market

Cosmetic Surgery and Procedure Market: https://www.factmr.com/report/cosmetic-surgery-and-procedure-market

Medical Beds Market: https://www.factmr.com/report/310/medical-bed-market

Coronary Microcatheters Market: https://www.factmr.com/report/3971/coronary-microcatheters-market

Patient Lifting Equipment Market: https://www.factmr.com/report/patient-lifting-equipment-market

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

This release was published on openPR.